Floatz logo

(1-(2-tetrahydrofuryl)-5-fluorouracil) and uracil 1:4

Poststroke/CVA Hemiparesis

Taipei Medical University WanFang HospitalmixtureN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Poststroke/CVA Hemiparesis cohort.

Asset / SponsorPhaseRating
Ctx Dp
ReNeuron Limited
Phase 2B
Armodafinil
Burke Rehabilitation Hospital
Phase 2B
CALCITONIN EEL
Asahi Kasei Therapeutics Corporation
Phase 2B
ctx0e03 drug product and delivery device
ReNeuron Limited
Phase 2CCC
TEONANACATL
Johns Hopkins University
Phase 1CC
Cyproheptadine
Shirley Ryan AbilityLab
N/AD

Same molecule, other indications

(1-(2-tetrahydrofuryl)-5-fluorouracil) and uracil 1:4 is also rated in:

MSI-L/MSSDormant
B
Indicative ·
63 / 100
View asset →
colon carcinomaDormant
B
Indicative ·
61 / 100
View asset →
colorectal cancerDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →